The authors regret that in the article “Hypothalamic orexin's role in exacerbated cutaneous vasodilation responses to an anxiogenic stimulus in a surgical menopause model” by Lauren Federici, Izabela Caliman, Andrei Molosh, Stephanie Fitz, William Truitt, Pascal Bonaventure, Janet Carpenter, Anantha Shekhar and Philip Johnson, which appeared on pages 127–137 of the March 2016 issue, the abstract and the 4th paragraph of the discussion state that the dual orexin receptor antagonist-12 (DORA-12) was a reformulated version of suvorexant. This is inaccurate. The DORA-12 is a close structural analog of suvorexant, but not a reformulation of suvorexant. This was correctly described in the methods Section 220.127.116.11. Additionally the following statement in the Discussion of the 4th paragraph regarding orexin 2 receptor (OX2R) is not accurate as written, “….OX2Rs which are exclusive to histaminergic neurons in the tuberomammillary nucleus….”. This implies that OX2Rs are only expressed in histamine neurons, which is inaccurate since OX2R's are expressed in many brain regions. A more accurate statement is that in situ hybridization studies OX2R mRNA is highly expressed in the tuberomammillary nucleus which contains histamine neurons, and OX1R mRNA is undetectable (Marcus et al., 2001 435:6–25, J. Comp. Neurol.). However, single cell PCR of histamine neurons shows that most histamine neurons have high expression of OX2R and weak expression of OX1Rs (Eriksson et al., 2001, 21(23):9273–9279, J. Neuroscience). They also demonstrated that both orexin A and orexin B strongly depolarize histamine neurons with no difference in potency. Since orexin-B primarily activates OXR2s, and orexin-A activates both OXRs, they conclude that OX2Rs are the physiologically more important OXR on histamine neurons, which is in keeping with the expression studies. The following should be added to disclosure section: PB is an employee of Janssen Research and Development, LLC. The authors would like to apologise for any inconvenience caused.
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Endocrine and Autonomic Systems
- Psychiatry and Mental health
- Biological Psychiatry